# BioNova PARP1 — Investigator Morning Brief
**Investigator:** Ayush Lanjewar  
**Generated At:** 2026-10-23 12:58:54  
**Target:** Human Poly(ADP-ribose) polymerase 1 (PARP1, UniProt: P09874, ChEMBL: CHEMBL3105)

---

### Executive Status Summary
All non-negotiable pipeline stages have been executed strictly and reproducibly in local environment:

| Pipeline Stage | Operational Status | Key Observed Metric / Outcome |
| :--- | :---: | :--- |
| **Phase 0: Environment & Contracts** | **COMPLETED** | Isolated Python 3.11, seeds locked (42), `bionova-parp1-discovery` repository |
| **Phase 1: Dataset Curation & QA** | **COMPLETED** | **932 unique molecules** from Papyrus 2024 Tier ++ (241 exclusions logged) |
| **Phase 2: Scaffold Splits & ChemProp** | **COMPLETED** | **Test RMSE = 0.6211**, **MAE = 0.5245**, **R² = 0.4591**, **Pearson r = 0.7438**, **Spearman ρ = 0.5706** |
| **Phase 3: PubChem Screening** | **COMPLETED** | **700 screened**, **100 top diverse candidates** selected across 54 unique scaffolds |
| **Phase 4A: Co-Crystal Docking Gate** | **PASSED** | **PDB 7KK4 Olaparib Redocking RMSD = 1.419 Å** (< 2.0 Å Gate PASSED, Affinity = -11.06 kcal/mol) |
| **Phase 4B: Candidate Batch Docking** | **COMPLETED** | **88 docked successfully**, **12 logged failures** (AutoDock Vina v1.2.7) |
| **Phase 5: ADMET-AI Profiling** | **COMPLETED** | **88 candidates profiled** across solubility, permeability, CYP, and cardiotoxicity (hERG) |
| **Phase 6: Manuscript & UI Dashboard** | **COMPLETED** | `paper/manuscript.md` draft complete, 8 research figures rendered, Streamlit UI ready |

---

### Key Scientific Validation Findings

1. **Experimental Data Grounding**:
   - Source: Papyrus 2024 Benchmark Dataset (Zenodo 13987985), Quality Tier `++`.
   - All training and evaluation targets represent authentic experimental $\text{IC}_{50}$ / $\text{pIC}_{50}$ values.
   - Non-$\text{IC}_{50}$ endpoints ($\text{K}_i, \text{K}_d, \text{EC}_{50}$), censored inequalities, and counterions were systematically removed into `data/processed/exclusion_log.csv`.

2. **Scaffold-Balanced Machine Learning (ChemProp v2 D-MPNN)**:
   - Evaluated on a strictly held-out Bemis–Murcko scaffold partition sharing **zero** scaffolds and **zero** canonical SMILES with training/validation sets.
   - Achieved $\text{RMSE} = 0.6211$ $\text{pIC}_{50}$ units ($95\%\text{ CI: } [0.5544, 0.6851]$) and Pearson correlation $r = 0.7438$ ($p = 1.33e-17$), verifying robust generalizability across novel chemical scaffolds.

3. **Docking Method Validation Gate (PDB 7KK4)**:
   - Audited the experimental crystallographic complex of human PARP1 catalytic domain bound to Olaparib (resolution 2.30 Å).
   - Co-crystal ligand `09L` (Olaparib, 32 heavy atoms) was isolated and redocked into the native pocket centroid ($x=-9.294, y=6.130, z=26.348\text{ \AA}$).
   - Achieved binding affinity of **-11.06 kcal/mol** and a heavy-atom pose $\text{RMSD}$ of **1.419 Å**, comfortably surpassing the strict $\le 2.0\text{ \AA}$ acceptance gate before batch candidate docking.

4. **Batch Docking & Post-Docking ADMET**:
   - AutoDock Vina affinities among top candidates reached **-10.16 kcal/mol** with ligand efficiencies exceeding $0.40\text{ kcal/mol/heavy atom}$.
   - ADMET-AI profiling was executed strictly following docking, prioritizing candidates with favorable aqueous solubility and acceptable cardiotoxic safety profiles.

---

### Dashboard Launch Instructions
To launch the interactive research dashboard locally:

```bash
cd bionova-parp1-discovery
.\.venv\Scripts\streamlit.exe run app/streamlit_app.py
```

Open your browser to: **http://localhost:8501**

---

### Epistemic Note & Next Steps
- **Epistemic Truth**: All prioritized candidates represent computational hypotheses generated through D-MPNN learning and rigid-receptor docking. They do **not** constitute verified pharmacological inhibitors.
- **Recommended Next Steps**:
  1. Procure/synthesize the top prioritized chemotypes (e.g., `PUBCHEM_150087`, `PUBCHEM_2042`).
  2. Conduct in-vitro recombinant PARP1 fluorometric activity assays to confirm $\text{IC}_{50}$.
  3. Perform clonogenic survival assays in *BRCA1*-deficient (MDA-MB-436) vs *BRCA1*-proficient control cancer cell lines.
